ID   MTP_HUMAN               Reviewed;         894 AA.
AC   P55157; A8K428; Q08AM4; Q6P5T3;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   10-MAY-2017, entry version 155.
DE   RecName: Full=Microsomal triglyceride transfer protein large subunit;
DE   Flags: Precursor;
GN   Name=MTTP; Synonyms=MTP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Small intestine;
RX   PubMed=8111381; DOI=10.1093/hmg/2.12.2109;
RA   Shoulders C.C., Brett D.J., Bayliss J.D., Narcisi T.M.E., Jarmuz A.,
RA   Grantham T.T., Leoni P.R.D., Bhattacharya S., Pease R.J., Cullen P.M.,
RA   Levi S., Byfield P.G.H., Purkiss P., Scott J.;
RT   "Abetalipoproteinemia is caused by defects of the gene encoding the 97
RT   kDa subunit of a microsomal triglyceride transfer protein.";
RL   Hum. Mol. Genet. 2:2109-2116(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=8361539; DOI=10.1038/365065a0;
RA   Sharp D., Blinderman L., Combs K.A., Kienzle B., Ricci B.,
RA   Wager-Smith K., Gil C.M., Turck C.W., Bouma M.-E., Rader D.J.,
RA   Aggerbeck L.P., Gregg R.E., Gordon D.A., Wetterau J.R.;
RT   "Cloning and gene defects in microsomal triglyceride transfer protein
RT   associated with abetalipoproteinaemia.";
RL   Nature 365:65-69(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7545943; DOI=10.1021/bi00197a005;
RA   Sharp D., Ricci B., Kienzle B., Lin M.C., Wetterau J.R.;
RT   "Human microsomal triglyceride transfer protein large subunit gene
RT   structure.";
RL   Biochemistry 33:9057-9061(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Blood vessel;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=7961826;
RA   Hagan D.L., Kienzle B., Jamil H., Hariharan N.;
RT   "Transcriptional regulation of human and hamster microsomal
RT   triglyceride transfer protein genes. Cell type-specific expression and
RT   response to metabolic regulators.";
RL   J. Biol. Chem. 269:28737-28744(1994).
RN   [8]
RP   SIMILARITY TO VITELLOGENINS.
RX   PubMed=7664034; DOI=10.1038/nsb0594-285;
RA   Shoulders C.C., Narcisi T.M.E., Read J., Chester S.A., Brett D.J.,
RA   Scott J., Anderson T.A., Levitt D.G., Banaszak L.J.;
RT   "The abetalipoproteinemia gene is a member of the vitellogenin family
RT   and encodes an alpha-helical domain.";
RL   Nat. Struct. Biol. 1:285-286(1994).
RN   [9]
RP   MUTAGENESIS OF CYS-878.
RX   PubMed=8533758;
RA   Narcisi T.M.E., Shoulders C.C., Chester S.A., Read J., Brett D.J.,
RA   Harrison G.B., Grantham T.T., Fox M.F., Povey S., de Bruin T.W.A.,
RA   Erkelens D.W., Muller D.P.R., Lloyd J.K., Scott J.;
RT   "Mutations of the microsomal triglyceride-transfer-protein gene in
RT   abetalipoproteinemia.";
RL   Am. J. Hum. Genet. 57:1298-1310(1995).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   FUNCTION, INTERACTION WITH P4HB, SUBCELLULAR LOCATION,
RP   CHARACTERIZATION OF VARIANTS ABL HIS-540; ILE-590; GLU-746 AND
RP   TYR-780, AND CHARACTERIZATION OF VARIANT ALA-384.
RX   PubMed=23475612; DOI=10.1194/jlr.M031658;
RA   Khatun I., Walsh M.T., Hussain M.M.;
RT   "Loss of both phospholipid and triglyceride transfer activities of
RT   microsomal triglyceride transfer protein in abetalipoproteinemia.";
RL   J. Lipid Res. 54:1541-1549(2013).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   VARIANT ABL HIS-540, VARIANTS GLN-297 AND ALA-384, CHARACTERIZATION
RP   VARIANT ABL HIS-540, CHARACTERIZATION VARIANTS GLN-297 AND ALA-384,
RP   MUTAGENESIS OF ARG-540, FUNCTION, AND INVOLVEMENT IN ABL.
RX   PubMed=8939939; DOI=10.1074/jbc.271.47.29945;
RA   Rehberg E.F., Samson-Bouma M.-E., Kienzle B., Blinderman L., Jamil H.,
RA   Wetterau J.R., Aggerbeck L.P., Gordon D.A.;
RT   "A novel abetalipoproteinemia genotype. Identification of a missense
RT   mutation in the 97-kDa subunit of the microsomal triglyceride transfer
RT   protein that prevents complex formation with protein disulfide
RT   isomerase.";
RL   J. Biol. Chem. 271:29945-29952(1996).
RN   [14]
RP   VARIANTS ABL HIS-540; ILE-590 AND GLU-746.
RX   PubMed=10679949;
RX   DOI=10.1002/(SICI)1098-1004(200003)15:3<294::AID-HUMU14>3.3.CO;2-5;
RA   Wang J., Hegele R.A.;
RT   "Microsomal triglyceride transfer protein (MTP) gene mutations in
RT   Canadian subjects with abetalipoproteinemia.";
RL   Hum. Mutat. 15:294-295(2000).
RN   [15]
RP   VARIANT ABL TYR-780.
RX   PubMed=10946006;
RA   Ohashi K., Ishibashi S., Osuga J., Tozawa R., Harada K., Yahagi N.,
RA   Shionoiri F., Iizuka Y., Tamura Y., Nagai R., Illingworth D.R.,
RA   Gotoda T., Yamada N.;
RT   "Novel mutations in the microsomal triglyceride transfer protein gene
RT   causing abetalipoproteinemia.";
RL   J. Lipid Res. 41:1199-1204(2000).
RN   [16]
RP   VARIANTS HIS-95; THR-128; GLU-244 AND GLN-297.
RX   PubMed=11792722;
RA   Ledmyr H., Karpe F., Lundahl B., McKinnon M., Skoglund-Andersson C.,
RA   Ehrenborg E.;
RT   "Variants of the microsomal triglyceride transfer protein gene are
RT   associated with plasma cholesterol levels and body mass index.";
RL   J. Lipid Res. 43:51-58(2002).
RN   [17]
RP   VARIANTS THR-128; ILE-168 AND GLN-297.
RX   PubMed=14732481;
RA   Lancellotti S., Di Leo E., Penacchioni J.Y., Balli F., Viola L.,
RA   Bertolini S., Calandra S., Tarugi P.;
RT   "Hypobetalipoproteinemia with an apparently recessive inheritance due
RT   to a 'de novo' mutation of apolipoprotein B.";
RL   Biochim. Biophys. Acta 1688:61-67(2004).
RN   [18]
RP   VARIANT ABL HIS-435, CHARACTERIZATION OF VARIANT ABL HIS-435,
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-435.
RX   PubMed=22236406; DOI=10.1194/jlr.M020024;
RA   Di Filippo M., Crehalet H., Samson-Bouma M.E., Bonnet V.,
RA   Aggerbeck L.P., Rabes J.P., Gottrand F., Luc G., Bozon D.,
RA   Sassolas A.;
RT   "Molecular and functional analysis of two new MTTP gene mutations in
RT   an atypical case of abetalipoproteinemia.";
RL   J. Lipid Res. 53:548-555(2012).
RN   [19]
RP   VARIANTS ABL ARG-264; HIS-528; CYS-540 AND SER-649, CHARACTERIZATION
RP   OF VARIANTS ABL ARG-264; HIS-528; CYS-540; HIS-540 AND SER-649,
RP   FUNCTION, INTERACTION WITH APOB AND P4HB, AND MUTAGENESIS OF TYR-528.
RX   PubMed=25108285; DOI=10.1016/j.bbalip.2014.08.001;
RA   Miller S.A., Burnett J.R., Leonis M.A., McKnight C.J.,
RA   van Bockxmeer F.M., Hooper A.J.;
RT   "Novel missense MTTP gene mutations causing abetalipoproteinemia.";
RL   Biochim. Biophys. Acta 1842:1548-1554(2014).
RN   [20]
RP   VARIANT ABL VAL-169, CHARACTERIZATION OF VARIANT ABL VAL-169,
RP   FUNCTION, INTERACTION WITH APOB AND P4HB, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF ASP-169; LYS-187 AND LYS-189.
RX   PubMed=26224785; DOI=10.1161/CIRCGENETICS.115.001106;
RA   Walsh M.T., Iqbal J., Josekutty J., Soh J., Di Leo E., Oezaydin E.,
RA   Guenduez M., Tarugi P., Hussain M.M.;
RT   "A novel abetalipoproteinemia missense mutation highlights the
RT   importance of N-Terminal beta-barrel in microsomal triglyceride
RT   transfer protein function.";
RL   Circ. Cardiovasc. Genet. 8:677-687(2015).
RN   [21]
RP   INTERACTION WITH APOB.
RX   PubMed=27206948; DOI=10.1016/j.jacl.2016.01.006;
RA   Miller S.A., Hooper A.J., Mantiri G.A., Marais D., Tanyanyiwa D.M.,
RA   McKnight J., Burnett J.R.;
RT   "Novel APOB missense variants, A224T and V925L, in a black South
RT   African woman with marked hypocholesterolemia.";
RL   J. Clin. Lipidol. 10:604-609(2016).
CC   -!- FUNCTION: Catalyzes the transport of triglyceride, cholesteryl
CC       ester, and phospholipid between phospholipid surfaces
CC       (PubMed:23475612, PubMed:8939939, PubMed:26224785,
CC       PubMed:25108285, PubMed:22236406). Required for the secretion of
CC       plasma lipoproteins that contain apolipoprotein B
CC       (PubMed:23475612, PubMed:8939939, PubMed:26224785).
CC       {ECO:0000269|PubMed:22236406, ECO:0000269|PubMed:23475612,
CC       ECO:0000269|PubMed:25108285, ECO:0000269|PubMed:26224785,
CC       ECO:0000269|PubMed:8939939}.
CC   -!- SUBUNIT: Heterodimer; heterodimerizes with the protein disulfide
CC       isomerase (P4HB/PDI) (PubMed:23475612, PubMed:26224785,
CC       PubMed:25108285). Interacts with APOB (PubMed:26224785,
CC       PubMed:25108285, PubMed:27206948). {ECO:0000269|PubMed:23475612,
CC       ECO:0000269|PubMed:25108285, ECO:0000269|PubMed:26224785,
CC       ECO:0000269|PubMed:27206948}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum
CC       {ECO:0000269|PubMed:22236406, ECO:0000269|PubMed:23475612,
CC       ECO:0000269|PubMed:26224785}. Note=Colocalizes with P4HB/PDI in
CC       the endoplasmic reticulum (PubMed:23475612, PubMed:26224785).
CC       {ECO:0000269|PubMed:23475612, ECO:0000269|PubMed:26224785}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P55157-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P55157-2; Sequence=VSP_056325, VSP_056326;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Liver and small intestine. Also found in
CC       ovary, testis and kidney. {ECO:0000269|PubMed:7961826}.
CC   -!- INDUCTION: Positively regulated by cholesterol and negatively
CC       regulated by insulin. {ECO:0000269|PubMed:7961826}.
CC   -!- DISEASE: Abetalipoproteinemia (ABL) [MIM:200100]: An autosomal
CC       recessive disorder of lipoprotein metabolism. Affected individuals
CC       produce virtually no circulating apolipoprotein B-containing
CC       lipoproteins (chylomicrons, VLDL, LDL, lipoprotein(A)).
CC       Malabsorption of the antioxidant vitamin E occurs, leading to
CC       spinocerebellar and retinal degeneration.
CC       {ECO:0000269|PubMed:10679949, ECO:0000269|PubMed:10946006,
CC       ECO:0000269|PubMed:22236406, ECO:0000269|PubMed:23475612,
CC       ECO:0000269|PubMed:25108285, ECO:0000269|PubMed:26224785,
CC       ECO:0000269|PubMed:8939939}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X75500; CAA53217.1; -; mRNA.
DR   EMBL; X59657; CAA42200.1; -; mRNA.
DR   EMBL; X83013; CAA58142.1; -; Genomic_DNA.
DR   EMBL; X83014; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83015; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83016; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83017; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83018; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83019; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83020; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83021; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83022; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83023; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83024; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83025; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83026; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83027; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83028; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83029; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; X83030; CAA58142.1; JOINED; Genomic_DNA.
DR   EMBL; AK290793; BAF83482.1; -; mRNA.
DR   EMBL; AC083902; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC062696; AAH62696.1; -; mRNA.
DR   EMBL; BC125110; AAI25111.1; -; mRNA.
DR   EMBL; BC125111; AAI25112.1; -; mRNA.
DR   CCDS; CCDS3651.1; -. [P55157-1]
DR   PIR; I38047; I38047.
DR   RefSeq; NP_000244.2; NM_000253.3. [P55157-1]
DR   RefSeq; NP_001287714.1; NM_001300785.1.
DR   UniGene; Hs.195799; -.
DR   ProteinModelPortal; P55157; -.
DR   BioGrid; 110641; 4.
DR   IntAct; P55157; 1.
DR   MINT; MINT-1537333; -.
DR   STRING; 9606.ENSP00000265517; -.
DR   BindingDB; P55157; -.
DR   ChEMBL; CHEMBL2569; -.
DR   DrugBank; DB01094; Hesperetin.
DR   DrugBank; DB04852; Implitapide.
DR   DrugBank; DB08827; Lomitapide.
DR   SwissLipids; SLP:000000411; -.
DR   iPTMnet; P55157; -.
DR   PhosphoSitePlus; P55157; -.
DR   BioMuta; MTTP; -.
DR   DMDM; 1709167; -.
DR   EPD; P55157; -.
DR   MaxQB; P55157; -.
DR   PaxDb; P55157; -.
DR   PeptideAtlas; P55157; -.
DR   PRIDE; P55157; -.
DR   Ensembl; ENST00000265517; ENSP00000265517; ENSG00000138823. [P55157-1]
DR   Ensembl; ENST00000422897; ENSP00000407350; ENSG00000138823. [P55157-2]
DR   Ensembl; ENST00000457717; ENSP00000400821; ENSG00000138823. [P55157-1]
DR   GeneID; 4547; -.
DR   KEGG; hsa:4547; -.
DR   UCSC; uc003hvb.4; human. [P55157-1]
DR   CTD; 4547; -.
DR   DisGeNET; 4547; -.
DR   GeneCards; MTTP; -.
DR   HGNC; HGNC:7467; MTTP.
DR   HPA; HPA051170; -.
DR   HPA; HPA054862; -.
DR   MalaCards; MTTP; -.
DR   MIM; 157147; gene.
DR   MIM; 200100; phenotype.
DR   neXtProt; NX_P55157; -.
DR   OpenTargets; ENSG00000138823; -.
DR   Orphanet; 14; Abetalipoproteinemia.
DR   Orphanet; 426; Familial hypobetalipoproteinemia.
DR   PharmGKB; PA164742099; -.
DR   eggNOG; KOG4337; Eukaryota.
DR   eggNOG; ENOG410YKCW; LUCA.
DR   GeneTree; ENSGT00390000011412; -.
DR   HOGENOM; HOG000113688; -.
DR   HOVERGEN; HBG006416; -.
DR   InParanoid; P55157; -.
DR   KO; K14463; -.
DR   PhylomeDB; P55157; -.
DR   TreeFam; TF328754; -.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-8866423; VLDL biosynthesis.
DR   GeneWiki; Microsomal_triglyceride_transfer_protein; -.
DR   GenomeRNAi; 4547; -.
DR   PRO; PR:P55157; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000138823; -.
DR   CleanEx; HS_MTTP; -.
DR   ExpressionAtlas; P55157; baseline and differential.
DR   Genevisible; P55157; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0005319; F:lipid transporter activity; IDA:UniProtKB.
DR   GO; GO:0005548; F:phospholipid transporter activity; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0006629; P:lipid metabolic process; TAS:ProtInc.
DR   GO; GO:0042158; P:lipoprotein biosynthetic process; TAS:Reactome.
DR   GO; GO:0015914; P:phospholipid transport; IDA:UniProtKB.
DR   GO; GO:0034377; P:plasma lipoprotein particle assembly; IDA:UniProtKB.
DR   GO; GO:0034197; P:triglyceride transport; IDA:UniProtKB.
DR   Gene3D; 2.30.230.10; -; 1.
DR   InterPro; IPR015819; Lipid_transp_b-sht_shell.
DR   InterPro; IPR001747; Lipid_transpt_N.
DR   InterPro; IPR015816; Vitellinogen_b-sht_N.
DR   InterPro; IPR011030; Vitellinogen_superhlx.
DR   Pfam; PF01347; Vitellogenin_N; 1.
DR   SMART; SM00638; LPD_N; 1.
DR   SUPFAM; SSF48431; SSF48431; 1.
DR   SUPFAM; SSF56968; SSF56968; 1.
DR   PROSITE; PS51211; VITELLOGENIN; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Disease mutation;
KW   Disulfide bond; Endoplasmic reticulum; Lipid transport; Lipid-binding;
KW   Polymorphism; Reference proteome; Signal; Transport.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    894       Microsomal triglyceride transfer protein
FT                                large subunit.
FT                                /FTId=PRO_0000041593.
FT   DOMAIN       28    659       Vitellogenin. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00557}.
FT   VAR_SEQ     134    151       EFYSYQNEAVAIENIKRG -> GRLDSTTFSPTSYFSSLQ
FT                                (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_056325.
FT   VAR_SEQ     152    894       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_056326.
FT   VARIANT      95     95       Q -> H (in dbSNP:rs61733139).
FT                                {ECO:0000269|PubMed:11792722}.
FT                                /FTId=VAR_014016.
FT   VARIANT      98     98       E -> D (in dbSNP:rs2306986).
FT                                /FTId=VAR_052961.
FT   VARIANT     128    128       I -> T (in dbSNP:rs3816873).
FT                                {ECO:0000269|PubMed:11792722,
FT                                ECO:0000269|PubMed:14732481}.
FT                                /FTId=VAR_014017.
FT   VARIANT     166    166       N -> S (in dbSNP:rs3792683).
FT                                /FTId=VAR_052962.
FT   VARIANT     168    168       V -> I (rare polymorphism;
FT                                dbSNP:rs61750974).
FT                                {ECO:0000269|PubMed:14732481}.
FT                                /FTId=VAR_022658.
FT   VARIANT     169    169       D -> V (in ABL; no loss on localization
FT                                to the endoplasmic reticulum; does not
FT                                reduce interaction with APOB; inhibits
FT                                interaction with P4HB/PDI; inhibits
FT                                phospholipid or triglyceride transfer
FT                                activity; inhibits apolipoprotein B
FT                                secretion).
FT                                {ECO:0000269|PubMed:26224785}.
FT                                /FTId=VAR_074553.
FT   VARIANT     244    244       Q -> E (in dbSNP:rs17599091).
FT                                {ECO:0000269|PubMed:11792722}.
FT                                /FTId=VAR_014018.
FT   VARIANT     264    264       G -> R (in ABL; unknown pathological
FT                                significance; does not reduce interaction
FT                                with P4HB/PDI and APOB; does not reduce
FT                                triglyceride transfer activity).
FT                                {ECO:0000269|PubMed:25108285}.
FT                                /FTId=VAR_074554.
FT   VARIANT     297    297       H -> Q (polymorphism; does not inhibit
FT                                apolipoprotein B secretion;
FT                                dbSNP:rs2306985).
FT                                {ECO:0000269|PubMed:11792722,
FT                                ECO:0000269|PubMed:14732481,
FT                                ECO:0000269|PubMed:8939939}.
FT                                /FTId=VAR_010640.
FT   VARIANT     354    354       E -> Q (in dbSNP:rs12933).
FT                                /FTId=VAR_014916.
FT   VARIANT     384    384       D -> A (polymorphism; no loss on
FT                                localization to the endoplasmic
FT                                reticulum; does not reduce interaction
FT                                with P4HB/PDI; reduces phospholipid or
FT                                triglyceride transfer activity; does not
FT                                inhibit apolipoprotein B secretion;
FT                                dbSNP:rs17029215).
FT                                {ECO:0000269|PubMed:23475612,
FT                                ECO:0000269|PubMed:8939939}.
FT                                /FTId=VAR_010641.
FT   VARIANT     435    435       L -> H (in ABL; no loss on localization
FT                                to the endoplasmic reticulum; inhibits
FT                                triglyceride transfer activity).
FT                                {ECO:0000269|PubMed:22236406}.
FT                                /FTId=VAR_074555.
FT   VARIANT     528    528       Y -> H (in ABL; does not reduce
FT                                interaction with P4HB/PDI and APOB;
FT                                inhibits triglyceride transfer activity).
FT                                {ECO:0000269|PubMed:25108285}.
FT                                /FTId=VAR_074556.
FT   VARIANT     540    540       R -> C (in ABL; does not reduce
FT                                interaction with P4HB/PDI and APOB;
FT                                inhibits triglyceride transfer activity;
FT                                dbSNP:rs372321643).
FT                                {ECO:0000269|PubMed:25108285}.
FT                                /FTId=VAR_074557.
FT   VARIANT     540    540       R -> H (in ABL; no loss on localization
FT                                to the endoplasmic reticulum; reduces
FT                                interaction with P4HB/PDI; inhibits
FT                                phospholipid or triglyceride transfer
FT                                activity; inhibits apolipoprotein B
FT                                secretion; dbSNP:rs199422220).
FT                                {ECO:0000269|PubMed:10679949,
FT                                ECO:0000269|PubMed:23475612,
FT                                ECO:0000269|PubMed:25108285,
FT                                ECO:0000269|PubMed:8939939}.
FT                                /FTId=VAR_010642.
FT   VARIANT     590    590       S -> I (in ABL; no loss on localization
FT                                to the endoplasmic reticulum; does not
FT                                reduce interaction with P4HB/PDI;
FT                                inhibits phospholipid or triglyceride
FT                                transfer activity; inhibits
FT                                apolipoprotein B secretion;
FT                                dbSNP:rs199422222).
FT                                {ECO:0000269|PubMed:10679949,
FT                                ECO:0000269|PubMed:23475612}.
FT                                /FTId=VAR_010643.
FT   VARIANT     649    649       N -> S (in ABL; unknown pathological
FT                                significance; does not reduce interaction
FT                                with P4HB/PDI and APOB; reduces
FT                                triglyceride transfer activity).
FT                                {ECO:0000269|PubMed:25108285}.
FT                                /FTId=VAR_074558.
FT   VARIANT     746    746       G -> E (in ABL; no loss on localization
FT                                to the endoplasmic reticulum; does not
FT                                reduce interaction with P4HB/PDI;
FT                                inhibits phospholipid or triglyceride
FT                                transfer activity; inhibits
FT                                apolipoprotein B secretion;
FT                                dbSNP:rs767833468).
FT                                {ECO:0000269|PubMed:10679949,
FT                                ECO:0000269|PubMed:23475612}.
FT                                /FTId=VAR_010644.
FT   VARIANT     780    780       N -> Y (in ABL; no loss on localization
FT                                to the endoplasmic reticulum; does not
FT                                reduce interaction with P4HB/PDI;
FT                                inhibits phospholipid or triglyceride
FT                                transfer activity; inhibits
FT                                apolipoprotein B secretion;
FT                                dbSNP:rs199422221).
FT                                {ECO:0000269|PubMed:10946006,
FT                                ECO:0000269|PubMed:23475612}.
FT                                /FTId=VAR_014019.
FT   MUTAGEN     169    169       D->E: No loss on localization to the
FT                                endoplasmic reticulum and does not reduce
FT                                interaction with APOB or P4HB/PDI, does
FT                                partially reduce phospholipid or
FT                                triglyceride transfer activity and
FT                                apolipoprotein B secretion.
FT                                {ECO:0000269|PubMed:26224785}.
FT   MUTAGEN     187    187       K->L: No loss on localization to the
FT                                endoplasmic reticulum and does not reduce
FT                                interaction with APOB, but inhibits
FT                                interaction with P4HB/PDI, phospholipid
FT                                or triglyceride transfer activity and
FT                                apolipoprotein B secretion.
FT                                {ECO:0000269|PubMed:26224785}.
FT   MUTAGEN     187    187       K->R: No loss on localization to the
FT                                endoplasmic reticulum, does not reduce
FT                                interaction with APOB or P4HB/PDI,
FT                                partially inhibits triglyceride transfer
FT                                activity, does not inhibit phospholipid
FT                                transfer activity and apolipoprotein B
FT                                secretion. {ECO:0000269|PubMed:26224785}.
FT   MUTAGEN     189    189       K->L: No loss on localization to the
FT                                endoplasmic reticulum and does not reduce
FT                                interaction with APOB, but inhibits
FT                                interaction with P4HB/PDI, phospholipid
FT                                or triglyceride transfer activity and
FT                                apolipoprotein B secretion.
FT                                {ECO:0000269|PubMed:26224785}.
FT   MUTAGEN     189    189       K->R: No loss on localization to the
FT                                endoplasmic reticulum, does not reduce
FT                                interaction with APOB or P4HB/PDI,
FT                                partially inhibits triglyceride transfer
FT                                activity, does not inhibit phospholipid
FT                                transfer activity and apolipoprotein B
FT                                secretion. {ECO:0000269|PubMed:26224785}.
FT   MUTAGEN     435    435       L->E: No loss on localization to the
FT                                endoplasmic reticulum. Inhibits
FT                                triglyceride transfer activity.
FT                                {ECO:0000269|PubMed:22236406}.
FT   MUTAGEN     435    435       L->V: No loss on localization to the
FT                                endoplasmic reticulum. Does not inhibit
FT                                triglyceride transfer activity.
FT                                {ECO:0000269|PubMed:22236406}.
FT   MUTAGEN     528    528       Y->F: Does not inhibit triglyceride
FT                                transfer activity.
FT                                {ECO:0000269|PubMed:25108285}.
FT   MUTAGEN     528    528       Y->K: Inhibits triglyceride transfer
FT                                activity. {ECO:0000269|PubMed:25108285}.
FT   MUTAGEN     540    540       R->A: Strongly reduces triglyceride
FT                                transfer activity.
FT                                {ECO:0000269|PubMed:25108285}.
FT   MUTAGEN     540    540       R->K: Does not inhibit triglyceride
FT                                transfer activity and apolipoprotein B
FT                                secretion. {ECO:0000269|PubMed:25108285,
FT                                ECO:0000269|PubMed:8939939}.
FT   MUTAGEN     878    878       C->S: Inhibits triglyceride transfer
FT                                activity. {ECO:0000269|PubMed:8533758}.
FT   CONFLICT    585    585       F -> L (in Ref. 2; CAA42200).
FT                                {ECO:0000305}.
SQ   SEQUENCE   894 AA;  99351 MW;  B20260C136BDAB9F CRC64;
     MILLAVLFLC FISSYSASVK GHTTGLSLNN DRLYKLTYST EVLLDRGKGK LQDSVGYRIS
     SNVDVALLWR NPDGDDDQLI QITMKDVNVE NVNQQRGEKS IFKGKSPSKI MGKENLEALQ
     RPTLLHLIHG KVKEFYSYQN EAVAIENIKR GLASLFQTQL SSGTTNEVDI SGNCKVTYQA
     HQDKVIKIKA LDSCKIARSG FTTPNQVLGV SSKATSVTTY KIEDSFVIAV LAEETHNFGL
     NFLQTIKGKI VSKQKLELKT TEAGPRLMSG KQAAAIIKAV DSKYTAIPIV GQVFQSHCKG
     CPSLSELWRS TRKYLQPDNL SKAEAVRNFL AFIQHLRTAK KEEILQILKM ENKEVLPQLV
     DAVTSAQTSD SLEAILDFLD FKSDSSIILQ ERFLYACGFA SHPNEELLRA LISKFKGSIG
     SSDIRETVMI ITGTLVRKLC QNEGCKLKAV VEAKKLILGG LEKAEKKEDT RMYLLALKNA
     LLPEGIPSLL KYAEAGEGPI SHLATTALQR YDLPFITDEV KKTLNRIYHQ NRKVHEKTVR
     TAAAAIILNN NPSYMDVKNI LLSIGELPQE MNKYMLAIVQ DILRFEMPAS KIVRRVLKEM
     VAHNYDRFSR SGSSSAYTGY IERSPRSAST YSLDILYSGS GILRRSNLNI FQYIGKAGLH
     GSQVVIEAQG LEALIAATPD EGEENLDSYA GMSAILFDVQ LRPVTFFNGY SDLMSKMLSA
     SGDPISVVKG LILLIDHSQE LQLQSGLKAN IEVQGGLAID ISGAMEFSLW YRESKTRVKN
     RVTVVITTDI TVDSSFVKAG LETSTETEAG LEFISTVQFS QYPFLVCMQM DKDEAPFRQF
     EKKYERLSTG RGYVSQKRKE SVLAGCEFPL HQENSEMCKV VFAPQPDSTS SGWF
//
